Panel Discussion: Uncovering the Latest Technology in Preclinical Modelling Through the Promise of Humanized Complement Models in Drug Development

  • Evaluating the utility of humanized complement models for testing complement inhibitors
  • Delving into their advantages for human targeted agents
  • Addressing key challenges such as incomplete humanization, low human protein expression and functional assay development
  • Understanding how humanized complement models can be used to inform complement inhibitor dose prediction